New drug shows promise for rare muscle disease

NCT ID NCT05669014

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called daxdilimab in 12 adults with dermatomyositis or anti-synthetase myositis that wasn't well controlled by standard treatments. The goal was to see if the drug could reduce disease activity and skin symptoms, and help lower steroid use over 24 weeks. The trial compared daxdilimab to a placebo to measure safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-SYNTHETASE INFLAMMATORY MYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy antisynthetase syndrome dermatomyositis myositis disease polymyositis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC INFLAMMATORY MYOSITIS

Contacts and locations

Locations

Accelerium, S. de R.L. de C.V. - PPDS

Monterrey, 64000, Mexico
Advanced Research Center, Inc.

Anaheim, California, 92805-5854, United States
Aintree University Hospital - NWCRN - PPDS

Liverpool, Merseyside, L9 7AL, United Kingdom
Centro Mineiro de Pesquisa - CMiP

Juiz de Fora, Minas Gerais, 36010-570, Brazil
Hospital Quironsalud Infanta Luisa

Seville, 41010, Spain
LMK Servicos Medicos SS

Porto Alegre, Rio Grande do Sul, 90480-000, Brazil
Revmatologicky ustav

Prague, Praha, Hlavní Mesto, 128 00, Czechia
Unidad de Investigacion de las Enfermedades Reumaticas S.A. De C.V.

Mexico City, Mexico
Western General Hospital Edinburgh - PPDS

Edinburgh, Midlothian, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.